Panacea Biotec Limited (PANACEABIO)
Please find attached Outcome of Board Meeting held on August 13, 2026.
Press Release - Q1FY27
- Consolidated revenue 19.96bn +20% y-y; PAT 0.40bn vs loss of 0.72bn y-y
- Vaccines segment profit before tax 0.75bn vs loss of 0.35bn y-y; formulations segment loss narrowed
- Exceptional income of 0.27bn recognized in consolidated results
- 42nd AGM scheduled for Sep 29, 2026 via VC; book closure Sep 25-29, 2026
- Management prepared results on going concern basis despite standalone negative retained earnings
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PANACEABIO — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PANACEABIO to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Panacea Biotec Limited
Important.
The summary above is generated automatically from Panacea Biotec Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.